| Name | Title | Contact Details |
|---|
Altos Solutions is a Los Altos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CrescentCare is an organization of health and wellness centers that is responding to the need for broader healthcare services in the Greater New Orleans area. CrescentCare uses proven interventions and evidence-based practices to improve outcomes for i...
First Health Group Corporation is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CODAC Behavioral Health Services of Pima County is a nonprofit 501(c)(3) organization that provides mental health and substance use disorder treatment and prevention programs to children, adults and families in Pima County. It is CODAC’s mission to work collaboratively with individuals, families and organizations to eliminate the harmful effects of substance use disorders, mental illness and abuse on their lives and families. CODAC was founded in 1970 and has evolved into a comprehensive service provider with a full continuum of mental health and substance use disorder treatment programs for youth (ages 12-17), young adults (ages 18-21) and adults (ages 22+) and their families at 10 conveniently located sites. CODAC’s prevention services are community-based and recognized as best-practices for preventing risky behaviors in Pima County youth and families.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.